The strategic questions behind diaDexus


SmithKline Beecham is gambling that its new 50/50 joint venture with Incyte Pharmaceuticals Inc. for molecular diagnostics discovery can make a viable business solely by developing and commercializing diagnostics. As a result of the deal's structure, diaDexus inevitably will produce some products that identify conditions for which SmithKline is developing therapeutics. However, diaDexus is intended as a separate entity meant to sell diagnostics in a market that may increasingly package tests with specific therapies developed using the same technologies.

As announced last week, SmithKline (Philadelphia, Penn.) will move its entire

Read the full 910 word article

How to gain access

Continue reading with a
two-week free trial.